The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

NCT ID: NCT06315023

Last Updated: 2025-05-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

450 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-06

Study Completion Date

2032-06-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis \> 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A maximum of 450 subjects will be enrolled with a target study population of at least 200 evaluable female and 200 evaluable male participants at the 12-month post-procedure follow-up visit. A maximum of 200 US sites. Sites will be selected that participate or will participate in the VQI PVI Registry. Follow up visits/assessments will be completed at 1, 12, 24-, 36-, 48-, and 60-months post-procedure. Study enrollment is expected to conclude over 4 years. Follow up data at 1 year is expected to conclude in 5 years from enrollment, with 5-year follow up expected to conclude in 9 years from enrollment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease Symptomatic Femoropopliteal Lesions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

As Treated

All patients that have received the therapy; patients treated within and outside the IFU criteria subgroups; male and female subgroups; and duplex imaging subgroups for arterial and venous observations.

DETOUR System

Intervention Type DEVICE

Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System

Imaging Cohort

Sites that are performing (arterial and venous) duplex ultrasound assessments according to the institution's standard practice will be asked to participate in the DUS imaging cohort. The Imaging sub-study will consist of 55 female and 55 male subjects from these sites. Duplex imaging at 1-, 12-, 24-, and 36-months post-procedure will be collected to assess the endpoints of graft patency and venous thrombus within the vein containing the graft (n=110).

DETOUR System

Intervention Type DEVICE

Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DETOUR System

Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fivos

UNKNOWN

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role collaborator

Society for Vascular Surgery Patient Safety Organization

OTHER

Sponsor Role collaborator

Endologix

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Salinas Valley Memorial Hospital

Salinas, California, United States

Site Status RECRUITING

University of Connecticut

Storrs, Connecticut, United States

Site Status RECRUITING

Medstar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status RECRUITING

Delray Medical Center

Delray Beach, Florida, United States

Site Status RECRUITING

Beth Isreal Deaconess Medical Center

Boston, Massachusetts, United States

Site Status RECRUITING

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Site Status RECRUITING

NYU Langone Medical Center

New York, New York, United States

Site Status RECRUITING

Cleveland Clinic Main Campus

Cleveland, Ohio, United States

Site Status RECRUITING

University of Pennsylvania

West Chester, Pennsylvania, United States

Site Status RECRUITING

Main Line Health

Wynnewood, Pennsylvania, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tammy Stiver

Role: CONTACT

5136731452

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP-0029

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.